RESPIVAC study: effectiveness of vaccination in preventing serious respiratory infections

Last updated on 11 June 2024

Objective of the RESPIVAC study

Respiratory viral infections are a public health problem. Vaccines exist or are being developed, and their efficacy has been evaluated in phase III trials. But the efficacy in certain vulnerable populations (over 65s, immunocompromised people, etc.), in severe/hospitalised forms of the disease, and according to the different variants, still require further research, in particular by carrying out ‘real population’ studies, known as phase IV trials.

The aim of the RESPIVAC study is to assess the efficacy of vaccination against viral respiratory infections in hospitalised adults.

In brief

Principal investigator
Dr. Liem Binh LUONG NGUYEN

Structure/teams
CIC of Vaccinology Cochin Pasteur (CIC 1417)
INSERM – SC10-US19 – Villejuif FRANCE

Status
Recruitment underway since January 2023 – Study to end in 2026

Pathologies
Severe acute respiratory syndrome (SARI); Viral respiratory infections

Sponsor
Inserm- ANRS MIE

Methodology of the RESPIVAC study

The RESPIVAC study is a national, prospective, multicentre, observational ‘test-negative design’ study. The primary objective is to evaluate the vaccine efficacy of vaccines against vaccine-preventable viral respiratory infections (influenza, COVID-19) in adult patients hospitalised for severe acute respiratory syndrome (SARI).

The secondary objectives are:

  • To estimate the prevalence of viral and bacterial co-infections and associated factors
  • To estimate the incidence of SARI by population group
  • Describe the clinical burden of HAIs in hospital.

The data collected includes socio-demographic data, hospital stays, health status and risk factors, vaccination status and virological results. The data will also be used as part of our participation in parallel international studies using a generic protocol used by all participating countries.

Latest news from the RESPIVAC study

The results of the RESPIVAC study, designed to measure the real-life effectiveness of influenza vaccination in adults hospitalised for severe respiratory syndrome, were presented at the 25th National Infectiology Days held in Deauville, France in 2024. The poster title was: “Influenza vaccine effectiveness 2022/2023 in adults hospitalised in France: results of a prospective real-life study”.

Read the summary